Literature DB >> 25941580

Overcoming immunosuppression to enhance a p53MVA vaccine.

Nicola Hardwick1, Vincent Chung2, Mihaela Cristea2, Joshua DI Ellenhorn3, Don J Diamond1.   

Abstract

A Phase I trial of a p53-targeting modified vaccinia Ankara (p53MVA) vaccine in patients afflicted with refractory gastrointestinal cancers demonstrated enhanced T-cell recognition of p53 following vaccination. However, this effect was transient suggesting that p53MVA requires combination with immunomodulatory agents to deliver clinical benefit. Here, we outline our rationale for combining p53MVA with immunomodulatory chemotherapy in a forthcoming trial.

Entities:  

Keywords:  DC, dendritic cells; MDSC, myeloid-derived suppressor cells; MVA; MVA, modified vaccinia Ankara; PD-1, programmed death receptor1; PDL-1, programmed death receptor 1 ligand; Tregs, regulatory T cells; clinical trial; gemcitabine; immunotherapy; ovarian cancer; p53

Year:  2014        PMID： 25941580      PMCID： PMC4292557          DOI： 10.4161/21624011.2014.958949

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.

Authors:  Nicola R Hardwick; Mary Carroll; Teodora Kaltcheva; Dajun Qian; Dean Lim; Lucille Leong; Peiguo Chu; Joseph Kim; Joseph Chao; Marwan Fakih; Yun Yen; Jonathan Espenschied; Joshua D I Ellenhorn; Don J Diamond; Vincent Chung
Journal:  Clin Cancer Res       Date:  2014-07-01       Impact factor: 12.531

2.  Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study.

Authors:  Renee Vermeij; Ninke Leffers; Baukje-Nynke Hoogeboom; Ineke L E Hamming; Rinze Wolf; Anna K L Reyners; Barbara H W Molmans; Harry Hollema; Joost Bart; Jan W Drijfhout; Jaap Oostendorp; Ate G J van der Zee; Cornelis J Melief; Sjoerd H van der Burg; Toos Daemen; Hans W Nijman
Journal:  Int J Cancer       Date:  2012-01-31       Impact factor: 7.396

Review 3.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Curr Opin Immunol       Date:  2012-01-09       Impact factor: 7.486

4.  Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.

Authors:  Miho Kaida; Yuriko Morita-Hoshi; Atsuko Soeda; Takako Wakeda; Yuni Yamaki; Yasushi Kojima; Hideki Ueno; Shunsuke Kondo; Chigusa Morizane; Masafumi Ikeda; Takuji Okusaka; Yoichi Takaue; Yuji Heike
Journal:  J Immunother       Date:  2011-01       Impact factor: 4.456

5.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

6.  Semi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammatory factors released from the tumor.

Authors:  Vegard Tjomsland; Anna Spångeus; Per Sandström; Kurt Borch; Davorka Messmer; Marie Larsson
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

7.  Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.

Authors:  Ninke Leffers; Annechien J A Lambeck; Marloes J M Gooden; Baukje-Nynke Hoogeboom; Rinze Wolf; Ineke E Hamming; Bouke G Hepkema; Pax H B Willemse; Barbara H W Molmans; Harry Hollema; Jan W Drijfhout; Willem J Sluiter; A Rob P M Valentijn; Loraine M Fathers; Jaap Oostendorp; Ate G J van der Zee; Cornelis J Melief; Sjoerd H van der Burg; Toos Daemen; Hans W Nijman
Journal:  Int J Cancer       Date:  2009-11-01       Impact factor: 7.396

8.  A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer.

Authors:  Yoshiki Hirooka; Akihiro Itoh; Hiroki Kawashima; Kazuo Hara; Koji Nonogaki; Toshifumi Kasugai; Eizaburo Ohno; Takuya Ishikawa; Hiroshi Matsubara; Masatoshi Ishigami; Yoshiaki Katano; Naoki Ohmiya; Yasumasa Niwa; Koji Yamamoto; Toru Kaneko; Mie Nieda; Kiyoshi Yokokawa; Hidemi Goto
Journal:  Pancreas       Date:  2009-04       Impact factor: 3.327

9.  Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer.

Authors:  Y Homma; K Taniguchi; M Nakazawa; R Matsuyama; R Mori; K Takeda; Y Ichikawa; K Tanaka; I Endo
Journal:  Clin Transl Oncol       Date:  2013-07-17       Impact factor: 3.405

10.  Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer.

Authors:  Atsuko Soeda; Yuriko Morita-Hoshi; Hiroaki Makiyama; Chigusa Morizane; Hideki Ueno; Masafumi Ikeda; Takuji Okusaka; Shizuka Yamagata; Noriko Takahashi; Ichinosuke Hyodo; Yoichi Takaue; Yuji Heike
Journal:  Jpn J Clin Oncol       Date:  2009-10-01       Impact factor: 3.019
  10 in total
  7 in total

1.  The mutational status of p53 can influence its recognition by human T-cells.

Authors:  Katerina Shamalov; Shlomo N Levy; Miryam Horovitz-Fried; Cyrille J Cohen
Journal:  Oncoimmunology       Date:  2017-01-31       Impact factor: 8.110

2.  Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer.

Authors:  Kaïdre Bendjama; Eric Quemeneur
Journal:  Hum Vaccin Immunother       Date:  2017-08-28       Impact factor: 3.452

Review 3.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

4.  Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab.

Authors:  Yuan Yuan; Ferdynand J Kos; Ting-Fang He; Hongwei H Yin; Mengsha Li; Nicola Hardwick; Kathryn Zurcher; Daniel Schmolze; Peter Lee; Raju K Pillai; Vincent Chung; Don J Diamond
Journal:  Oncoimmunology       Date:  2017-08-11       Impact factor: 8.110

5.  Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers.

Authors:  V Chung; F J Kos; N Hardwick; Y Yuan; J Chao; D Li; J Waisman; M Li; K Zurcher; P Frankel; D J Diamond
Journal:  Clin Transl Oncol       Date:  2018-08-09       Impact factor: 3.340

Review 6.  Putting p53 in Context.

Authors:  Edward R Kastenhuber; Scott W Lowe
Journal:  Cell       Date:  2017-09-07       Impact factor: 41.582

Review 7.  The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy.

Authors:  Galaxia M Rodriguez; Kristianne J C Galpin; Curtis W McCloskey; Barbara C Vanderhyden
Journal:  Cancers (Basel)       Date:  2018-07-24       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.